PCA3 Reference Set Application: Arul Chinnaiyan (2020)
- Abbreviated Name
- PCA3 Ref Set App: Chinnaiyan (2020)
- Lead Investigator
- Chinnaiyan, Arul M. — University of Michigan
- Coordinating Investigator
- Feng, Ziding — Fred Hutchinson Cancer Center
- Involved Investigators
Abstact
No abstract availalbe.
Aims
Biopsy-naïve men provided post-digital rectal examination (DRE) urine prior to biopsy. MPS was calculated using the validated, locked multivariable model including only serum PSA, urinary PCA3, and urinary TMPRSS2:ERG. The MPS threshold approximating 95% sensitivity for GG ≥2 cancer was identified in a training cohort, and performance was measured in two external validation cohorts. We assessed the (i) overall biopsy-referral population and (ii) population meeting guideline-based testing criteria (ie, PSA 3-10; or PSA <3 with suspicious DRE).
Analytic Method
No analytic method available.
Outcome
The MyProstateScore (MPS) test was validated for improved detection of clinically-significant (Grade Group [GG] ≥2) prostate cancer relative to PSA-based risk calculators. We sought to validate an optimal MPS threshold for clinical use in ruling-out GG ≥2 cancer in men referred for biopsy.
Publications
Biomarkers
- No biomarkers available at this time for this protocol.
Data Collections
- No data collections available at this time for this protocol.
Team Project
- Start Date
- Jan 1 2020
- Finish Date
- Oct 20 2020
- Protocol ID
- 477
- Protocol Type
- Validation
- Field of Research
- Genomics
- Collaborative Group
- Prostate and Urologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of prostate